Eli Lilly and Company (NYSE:LLY) Shares Sold by Keynote Financial Services LLC

Keynote Financial Services LLC decreased its position in shares of Eli Lilly and Company (NYSE:LLY) by 12.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,775 shares of the company’s stock after selling 241 shares during the period. Eli Lilly and Company accounts for approximately 1.2% of Keynote Financial Services LLC’s portfolio, making the stock its 20th biggest holding. Keynote Financial Services LLC’s holdings in Eli Lilly and Company were worth $1,573,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. China Universal Asset Management Co. Ltd. boosted its position in Eli Lilly and Company by 19.6% during the first quarter. China Universal Asset Management Co. Ltd. now owns 9,897 shares of the company’s stock worth $7,699,000 after purchasing an additional 1,620 shares in the last quarter. Quent Capital LLC grew its holdings in shares of Eli Lilly and Company by 5.3% during the 1st quarter. Quent Capital LLC now owns 4,943 shares of the company’s stock worth $3,846,000 after purchasing an additional 249 shares during the period. Empowered Funds LLC increased its position in shares of Eli Lilly and Company by 8.3% in the first quarter. Empowered Funds LLC now owns 32,027 shares of the company’s stock worth $24,916,000 after acquiring an additional 2,452 shares in the last quarter. Guardian Asset Advisors LLC increased its holdings in Eli Lilly and Company by 2.7% in the 1st quarter. Guardian Asset Advisors LLC now owns 3,415 shares of the company’s stock valued at $2,657,000 after purchasing an additional 91 shares in the last quarter. Finally, Prospera Private Wealth LLC purchased a new stake in shares of Eli Lilly and Company during the 1st quarter valued at about $260,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $797.58 on Friday. The firm’s 50 day simple moving average is $901.75 and its 200 day simple moving average is $867.32. The firm has a market capitalization of $757.16 billion, a price-to-earnings ratio of 86.22, a P/E/G ratio of 3.05 and a beta of 0.43. The company has a current ratio of 1.27, a quick ratio of 0.97 and a debt-to-equity ratio of 2.03. Eli Lilly and Company has a 1 year low of $561.65 and a 1 year high of $972.53.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The company had revenue of $11.44 billion during the quarter, compared to analyst estimates of $12.09 billion. During the same quarter in the previous year, the business posted $0.10 earnings per share. The company’s revenue for the quarter was up 20.4% on a year-over-year basis. As a group, research analysts expect that Eli Lilly and Company will post 13.21 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be given a $1.30 dividend. The ex-dividend date is Friday, November 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.65%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 56.22%.

Analyst Upgrades and Downgrades

Several research analysts recently commented on LLY shares. JPMorgan Chase & Co. boosted their price target on Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an “overweight” rating in a research note on Friday, September 13th. Truist Financial increased their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a “buy” rating in a research note on Thursday, October 10th. Redburn Atlantic raised shares of Eli Lilly and Company to a “hold” rating in a report on Monday. BMO Capital Markets increased their price target on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a research note on Friday, August 9th. Finally, Evercore ISI upgraded shares of Eli Lilly and Company to a “hold” rating in a research note on Thursday, September 5th. Four investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $1,008.41.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.